|

Levoleucovorin Clinical Trials

4 actively recruiting trials across 4 locations

Also known as: CL-307,782, Elvorine, Isovorin, Levofolene, Levorin, FUSILEV®, Isovorin, L-Leucovorin +4 more

Pipeline

Phase 2: 1Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Merck Sharp & Dohme LLC2
  • Seagen, a wholly owned subsidiary of Pfizer1
  • National Cancer Institute (NCI)1

Indications

  • Cancer4
  • Gastroesophageal Junction1
  • Gastroesophageal Adenocarcinoma1
  • B Acute Lymphoblastic Leukemia1
  • Esophageal Neoplasms1

Birmingham, Alabama1 trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Glendale, Arizona1 trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Palo Verde Hematology Oncology

Phase 3

Tucson, Arizona1 trial

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)

Phase 1/2

Pittsburgh, Pennsylvania1 trial

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

UPMC Hillman Cancer Center ( Site 1904)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.